SERPING1 and hereditary angioedema: The role of excess KKS activation in HAE-C1INH pathophysiology has been validated by the approval of therapies that include C1INH protein replacement products, a bradykinin B2 receptor antagonist (icatibant), and PKa inhibitors (ecallantide, lanadelumab, and berotralstat).